Answers are grounded in this paper and cite their sources.
While important progress was made regarding the treatment of systemic sclerosis (SSc), there is still no evidence-based disease-modifying treatment available for SSc-related gastrointestinal (GI) manifestations. We aimed to identify an association between immunosuppressive therapy and the the severity of GI symptoms, measured by the University of California at Los Angeles/Scleroderma Clinical Trial Consortium Gastro-Intestinal Tract instrument 2.0 (GIT).
No takes yet. Share an insight, caveat, or question.
Stamm et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: